The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.
Human genetic studies have demonstrated that polymorphisms in different complement proteins can increase the risk for developing AMD. There are three pathways of complement activation, classical (CP), alternative (AP), and lectin (LP), which all activate a final common pathway. Proteins encoded by the AMD risk genes participate in the AP (CFB), CP/LP (C2), or in the AP and final common pathway (C3). Here we tested which pathway is essential in mouse laser-induced CNV. CNV was analyzed using single complement pathway knockouts (i.e., eliminating one complement pathway at a time), followed by a double knockout in which only the AP is present, and the CP and LP are disabled, using molecular, histological and electrophysiological outcomes. First, single-gene knockouts were analyzed and compared to wild type mice; C1q(-/-) (no CP), MBL(-/-) (no LP), and CFB(-/-) (no AP). Six days after the laser-induced lesion, mice without a functional AP had reduced CNV progression (P<0.001) and preserved ERG amplitudes, whereas those without a functional CP or LP were indistinguishable from the wild type controls (P>0.3). Second, AP-only mice (C1q(-/-)MBL(-/-)) were as protected from developing CNV as the CFB(-/-) mice. The degree of pathology in each strain correlated with protein levels of the angiogenic and anti-angiogenic protein VEGF and PEDF, respectively, as well as levels of terminal pathway activation product C5a, and C9. The analysis of complement activation pathways in mouse laser-induced CNV allows for the following conclusions. Comparing the single pathway knockouts with those having only a functional AP showed: (1) that AP activation is necessary, but not alone sufficient for injury; and (2) that initial complement activation proceeds via both the LP and CP. Thus, these data indicate an important role for the AP in the generation of complement-dependent injury in the RPE and choroid via amplification of CP- and LP-initiated complement activation. Improving our understanding of the local regulation of this pathway in the eye is essential for developing improved treatment approaches for AMD.
Department of Ophthalmology, Medical University of South Carolina, Charleston, SC 29425, United States. rohrer@musc.edu
Bärbel
B
Rohrer
Beth
B
Coughlin
Kannan
K
Kunchithapautham
Qin
Q
Long
Stephen
S
Tomlinson
Kazue
K
Takahashi
V Michael
VM
Holers
D043925:Angiogenesis Inducing Agents / Q000378:metabolism; D000818:Animals; D020256:Choroidal Neovascularization / Q000276:immunology* / Q000473:pathology* / Q000503:physiopathology; D003170:Complement Pathway, Alternative / Q000276:immunology*; D003165:Complement System Proteins / Q000235:genetics / Q000378:metabolism; D004596:Electroretinography; D005786:Gene Expression Regulation; D007834:Lasers; D051379:Mice; D020419:Photoreceptor Cells, Vertebrate / Q000276:immunology / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012160:Retina / Q000276:immunology* / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
D043925:Angiogenesis Inducing Agents; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D003165:Complement System Proteins
J Biol Chem. 2009 Jun 19;284(25):16939-16947
19386604
Nature. 2008 Apr 3;452(7187):591-7
18368052
J Immunol. 2006 Aug 1;177(3):1872-8
16849499
Vis Neurosci. 2003 Mar-Apr;20(2):211-20
12916741
J Immunol. 2005 Mar 15;174(6):3220-6
15749852
PLoS One. 2009 Nov 20;4(11):e7945
19936204
Nat Genet. 2006 Apr;38(4):458-62
16518403
Am J Clin Nutr. 1995 Dec;62(6 Suppl):1448S-1461S
7495246
J Comp Neurol. 2005 Mar 14;483(3):263-77
15682400
Immunobiology. 2011 Jan-Feb;216(1-2):96-102
20399528
J Immunol. 2007 Feb 1;178(3):1783-90
17237428
Clin Exp Immunol. 2010 Jan;159(1):100-8
19843088
Clin Exp Immunol. 2006 Jun;144(3):512-20
16734621
Br J Ophthalmol. 2010 Jul;94(7):915-7
20606025
Science. 2005 Apr 15;308(5720):419-21
15761120
Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32
15870199
Curr Drug Targets. 2008 Feb;9(2):158-64
18288967
Science. 2005 Apr 15;308(5720):385-9
15761122
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8720-5
9238044
Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S440-4
16237644
Vis Neurosci. 2006 Jan-Feb;23(1):91-7
16597353
Clin Exp Ophthalmol. 2006 Aug;34(6):590-5
16925708
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):533-9
18806297
PLoS One. 2008;3(11):e3554
18978936
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3056-64
19264882
Arch Ophthalmol. 2002 Nov;120(11):1435-42
12427055
Annu Rev Immunol. 2003;21:547-78
12524383
Annu Rev Biochem. 1988;57:321-47
3052276
Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1853-9
19749170
J Clin Invest. 2003 Dec;112(11):1644-54
14660741
J Clin Invest. 2010 Oct;120(10):3545-54
20941861
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1178-83
18326747
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2328-33
16452172
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1190-7
19834034
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5818-27
19661236
Immunology. 2005 Jul;115(3):422-30
15946260
Immunobiology. 2006;211(10):759-66
17113913
Blood. 2010 Nov 25;116(22):4395-403
20625009
J Immunol. 2005 May 15;174(10):6373-80
15879138
Can J Ophthalmol. 2005 Jun;40(3):277-87
15947797
J Biol Chem. 2003 Oct 24;278(43):42027-35
12923198
Exp Eye Res. 2006 Aug;83(2):380-9
16626700
Am J Pathol. 2005 Jan;166(1):241-51
15632016
J Biol Chem. 2010 Oct 29;285(44):33826-33
20736175
PLoS One. 2008;3(11):e3813
19043567
Prog Retin Eye Res. 2001 Nov;20(6):705-32
11587915
Exp Eye Res. 2001 Dec;73(6):887-96
11846519
Am J Ophthalmol. 2002 Aug;134(2):220-7
12140029
J Immunol. 2007 Sep 15;179(6):4101-9
17785849
Science. 2005 Apr 15;308(5720):421-4
15761121
Exp Eye Res. 2006 Jan;82(1):99-110
16019000
Am J Ophthalmol. 2002 Sep;134(3):411-31
12208254
Cell Tissue Res. 2011 Jan;343(1):227-35
20838815
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18751-6
19841260
Stroke. 2005 Oct;36(10):2244-50
16179576
Immunopharmacology. 2000 Aug;49(1-2):149-57
10904114
Clin Exp Immunol. 2004 Dec;138(3):439-46
15544620
Invest Ophthalmol Vis Sci. 2002 May;43(5):1567-73
11980875
Br J Ophthalmol. 2004 Sep;88(9):1217-22
15317719
J Immunol. 2006 Feb 1;176(3):1305-10
16424154
Clin Exp Optom. 2008 Sep;91(5):427-37
18637105